MDPI - Publisher of Open Access Journals

12 pages, 393 KB

Open AccessArticle

Mystic Christianity and Cosmic Integration: On a Pilgrim Trail with John Moriarty

by Mairéad Nic Craith, Ullrich Kockel, Mary McGillicuddy and Amanda Carmody

Religions 2024, 15(3), 307; https://doi.org/10.3390/rel15030307 - 29 Feb 2024

Viewed by 4163

This essay takes initial steps on a journey with an Irish eco-spiritual philosopher, the late John Moriarty. As a gateway into his broader oeuvre and way of thinking, we explore Moriarty’s image of the Christian mystical Easter journey—the Triduum Sacrum—as a vision for humanity and the planet. After briefly reviewing his spiritual biography, we consider Moriarty’s re-framing of the story as a journey to the bottom of a symbolic Grand Canyon, a mystical trail beyond historical time to a primordial unity before the evolution of the species. There, the total integration of the natural ecumene is experienced. For Moriarty, this journey leads not only into the past, but prefigures a pilgrimage that everyone can—and should—take. Analyzing primarily his own writing, we highlight the intercultural roots and ecumenical connections of Moriarty’s work, which draws extensively on spiritual traditions and contemporary debates from across the world. On that basis, we sign-post directions for further research into a potential post-Christian ecology as a new way of thinking about the earth and our role on it, based on an attitude of Gelassenheit. Full article

(This article belongs to the Special Issue Religion and Planetary Climate Crisis)

15 pages, 2093 KB

Open AccessReview

The Long Scientific Journey of Sirolimus (Rapamycin): From the Soil of Easter Island (Rapa Nui) to Applied Research and Clinical Trials on β-Thalassemia and Other Hemoglobinopathies

by Roberto Gambari, Cristina Zuccato, Lucia Carmela Cosenza, Matteo Zurlo, Jessica Gasparello, Alessia Finotti, Maria Rita Gamberini and Marco Prosdocimi

Biology 2023, 12(9), 1202; https://doi.org/10.3390/biology12091202 - 2 Sep 2023

Cited by 7 | Viewed by 4633

Abstract

In this review article, we present the fascinating story of rapamycin (sirolimus), a drug able to induce γ-globin gene expression and increased production of fetal hemoglobin (HbF) in erythroid cells, including primary erythroid precursor cells (ErPCs) isolated from β-thalassemia patients. For this reason, rapamycin is considered of great interest for the treatment of β-thalassemia. In fact, high levels of HbF are known to be highly beneficial for β-thalassemia patients. The story of rapamycin discovery began in 1964, with METEI, the Medical Expedition to Easter Island (Rapa Nui). During this expedition, samples of the soil from different parts of the island were collected and, from this material, an antibiotic-producing microorganism (Streptomyces hygroscopicus) was identified. Rapamycin was extracted from the mycelium with organic solvents, isolated, and demonstrated to be very active as an anti-bacterial and anti-fungal agent. Later, rapamycin was demonstrated to inhibit the in vitro cell growth of tumor cell lines. More importantly, rapamycin was found to be an immunosuppressive agent applicable to prevent kidney rejection after transplantation. More recently, rapamycin was found to be a potent inducer of HbF both in vitro using ErPCs isolated from β-thalassemia patients, in vivo using experimental mice, and in patients treated with this compound. These studies were the basis for proposing clinical trials on β-thalassemia patients. Full article

(This article belongs to the Special Issue Thalassemia Research: Focus on Novel Molecular Insights and Clinical Perspectives)

► Show Figures

Graphical abstract

Search Results (2)

Further Information

Guidelines

MDPI Initiatives

Follow MDPI

Saved Queries

Search Filter Reset All

Years

Feature Papers

Subjects

Journals

Article Types

Countries / Regions

Search Results (2)

Further Information

Guidelines

MDPI Initiatives

Follow MDPI